New treatment extends life of melanoma patients by an average of four months in large clinical trial

A therapy that multiplies the effect of a natural disease-fighting antibody has extended by an average of four months the lives of patients with metastatic melanoma in a large, international clinical trial. The researchers presented their findings yesterday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and they are published in the New England Journal of Medicine on-line.read more

Read the whole article on Harvard Science

More from Harvard Science